For the quarter ended June 30, 2008
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended June 30, 2008

Commission File Number 1-6926

 

 

C. R. BARD, INC.

(Exact name of registrant as specified in its charter)

 

 

 

New Jersey  

730 Central Avenue

Murray Hill, New Jersey 07974

  22-1454160
(State of incorporation)  

(Address of principal

executive offices)

 

(I.R.S. Employer

Identification No.)

Registrant’s telephone number, including area code: (908) 277-8000

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer  x

 

Accelerated filer  ¨

Non-accelerated filer  ¨

 

Smaller reporting company   ¨

(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class

 

Outstanding at June 30, 2008

Common Stock - $0.25 par value

 

99,339,845

 

 

 


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

INDEX

 

          PAGE NO.

PART I – FINANCIAL INFORMATION

  

Item 1.

  

Financial Statements (unaudited)

  
  

Condensed Consolidated Statements of Income for the Quarter and Six Months Ended June 30, 2008 and 2007

   3
  

Condensed Consolidated Balance Sheets – June 30, 2008 and December 31, 2007

   4
  

Condensed Consolidated Statements of Shareholders’ Investment for the Six Months Ended June 30, 2008 and 2007

   5
  

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2008 and 2007

   6
  

Notes to Condensed Consolidated Financial Statements

   7

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

   16

Item 3.

  

Quantitative and Qualitative Disclosures About Market Risk

   27

Item 4.

  

Controls and Procedures

   27

PART II – OTHER INFORMATION

  

Item 1.

  

Legal Proceedings

   29

Item 2.

  

Unregistered Sales of Equity Securities and Use of Proceeds

   30

Item 4.

  

Submission of Matters to a Vote of Security Holders

   31

Item 5.

  

Other Information

   31

Item 6.

  

Exhibits

   31

Signatures

   32

 

2


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(dollars in thousands except per share amounts, unaudited)

 

    Quarter
Ended June 30,
    Six Months Ended June 30,  
      2008     2007     2008   2007  

Net sales

  $ 617,100   $ 545,700     $ 1,201,100   $ 1,073,900  

Costs and expenses:

       

Cost of goods sold

    243,600     216,600       469,100     423,100  

Marketing, selling and administrative expense

    180,800     160,500       349,700     314,200  

Research and development expense

    38,200     35,100       124,000     65,200  

Interest expense

    3,000     3,000       6,000     5,900  

Other (income) expense, net

    32,600     (8,800 )     28,600     (16,200 )
                           

Total costs and expenses

    498,200     406,400       977,400     792,200  
                           

Income from continuing operations before income taxes

    118,900     139,300       223,700     281,700  

Income tax provision

    41,000     41,800       67,800     82,600  
                           

Income from continuing operations

    77,900     97,500       155,900     199,100  
                           

Income on discontinued operations

    —       —         —       —    
                           

Net income

  $ 77,900   $ 97,500     $ 155,900   $ 199,100  
                           

Basic earnings per share:

       

Income from continuing operations

  $ 0.78   $ 0.94     $ 1.56   $ 1.93  

Net income per share

  $ 0.78   $ 0.94     $ 1.56   $ 1.93  
                           

Diluted earnings per share:

       

Income from continuing operations

  $ 0.76   $ 0.91     $ 1.52   $ 1.86  

Net income per share

  $ 0.76   $ 0.91     $ 1.52   $ 1.86  
                           

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands except share and per share amounts, unaudited)

 

    June 30,
2008
  December 31,
2007

ASSETS

   

Current assets:

   

Cash and cash equivalents

  $ 427,600   $ 488,400

Short-term investments

    6,700     82,200

Accounts receivable, less allowances of $13,600 and $15,600, respectively

    402,900     362,000

Inventories

    283,300     244,700

Short-term deferred tax assets

    43,100     36,500

Other current assets

    56,000     28,200
           

Total current assets

    1,219,600     1,242,000
           

Property, plant and equipment, at cost

    602,200     577,100

Less accumulated depreciation and amortization

    255,500     232,500
           

Net property, plant and equipment

    346,700     344,600

Intangibles, net

    856,500     773,000

Deferred tax assets

    41,200     44,400

Other assets

    74,100     71,500
           

Total assets

  $ 2,538,100   $ 2,475,500
           

LIABILITIES AND SHAREHOLDERS’ INVESTMENT

   

Current liabilities:

   

Short-term borrowings and current maturities of long-term debt

  $ —     $ 800

Accounts payable

    53,000     50,200

Accrued compensation and benefits

    82,200     99,800

Accrued expenses

    140,200     118,500

Income taxes payable

    11,000     12,400
           

Total current liabilities

    286,400     281,700
           

Long-term debt

    149,800     149,800

Other long-term liabilities

    189,900     175,800

Deferred income taxes

    21,100     20,200

Commitments and contingencies

    —       —  

Shareholders’ investment:

   

Preferred stock, $1 par value, authorized 5,000,000 shares; none issued

    —       —  

Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 99,339,845 shares at June 30, 2008 and 100,191,117 shares at December 31, 2007

    24,800     25,000

Capital in excess of par value

    902,000     824,200

Retained earnings

    900,800     956,300

Accumulated other comprehensive income

    63,300     42,500
           

Total shareholders’ investment

    1,890,900     1,848,000
           

Total liabilities and shareholders’ investment

  $ 2,538,100   $ 2,475,500
           

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ INVESTMENT

(dollars in thousands except share amounts, unaudited)

 

    Common Stock     Capital in
Excess of Par
Value
  Retained
Earnings
    Accumulated
Other Comp.
Inc.
    Total  
    Shares     Amount          

Balance at December 31, 2007

  100,191,117     $ 25,000     $ 824,200   $ 956,300     $ 42,500     $ 1,848,000  

Net income

          155,900         155,900  

Available for sale securities (net of $500 taxes)

            (800 )     (800 )

Change in derivative instruments designated as cash flow hedges (net of $200 taxes)

            200       200  

Amortization of items included in net periodic benefit cost (net of $800 taxes)

            1,300       1,300  

Foreign currency translation adjustment

            20,100       20,100  
                             

Total comprehensive income

          155,900       20,800       176,700  

Issuance of common stock

  1,017,220       200       36,600         36,800  

Share-based compensation

        19,600         19,600  

Purchase of common stock for treasury

  (1,868,492 )     (400 )       (180,400 )       (180,800 )

Cash dividends declared in current year

          (31,000 )       (31,000 )

Tax benefit relating to share-based compensation plans

        21,600         21,600  
                                           

Balance at June 30, 2008

  99,339,845     $ 24,800     $ 902,000   $ 900,800     $ 63,300     $ 1,890,900  
                                           

Balance at December 31, 2006

  103,155,437     $ 25,800     $ 659,700   $ 1,026,800     $ (14,300 )   $ 1,698,000  

Net income

          199,100         199,100  

Available for sale securities

            (100 )     (100 )

Change in derivative instruments designated as cash flow hedges

            200       200  

Amortization of items included in net periodic benefit cost (net of $1,900 taxes)

            1,000       1,000  

Foreign currency translation adjustment

            8,700       8,700  
                             

Total comprehensive income

         
199,100
 
    9,800       208,900  

Issuance of common stock

  1,183,734       200       43,200         43,400  

Share-based compensation

        22,700         22,700  

Purchase of common stock for treasury

  (980,000 )     (200 )       (81,100 )      
(81,300
)

Adjustment for the adoption of FIN 48

          5,300         5,300  

Cash dividends declared in current year

          (30,200 )       (30,200 )

Tax benefit relating to share-based compensation plans

        24,000         24,000  
                                           

Balance at June 30, 2007

  103,359,171     $ 25,800     $ 749,600   $ 1,119,900     $ (4,500 )   $ 1,890,800  
                                           

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands, unaudited)

 

     Six Months
Ended June 30,
 
       2008         2007    

Cash flows from operating activities from continuing operations:

    

Net income

   $ 155,900     $ 199,100  

Income on discontinued operations

     —         —    
                

Income from continuing operations

     155,900       199,100  

Adjustments to reconcile income from continuing operations to derive net cash provided from continuing operating activities, net of acquired businesses:

    

Depreciation and amortization

     45,000       38,800  

Purchased research and development

     49,300       1,600  

Non-cash charge related to asset disposition

     40,500       —    

Deferred income taxes

     (25,500 )     (3,000 )

Share-based compensation

     19,700       22,700  

Inventory reserves and provision for doubtful accounts

     5,600       5,200  

Other noncash items

     (500 )     (1,700 )

Changes in assets and liabilities:

    

Accounts receivable

     (29,400 )     (4,800 )

Inventories

     (30,800 )     (17,000 )

Current liabilities

     (16,000 )     10,700  

Other, net

     (8,900 )     (13,900 )
                

Net cash provided by operating activities from continuing operations

     204,900       237,700  
                

Cash flows from investing activities from continuing operations:

    

Capital expenditures

     (24,000 )     (25,200 )

Change in short-term investments, net

     75,500       (21,600 )

Net proceeds from investments

     —         200  

Payments made for purchases of businesses, net of cash acquired

     (140,600 )     (42,000 )

Payments made for intangibles

     (13,800 )     (16,600 )
                

Net cash used in investing activities from continuing operations

     (102,900 )     (105,200 )
                

Cash flows from financing activities from continuing operations:

    

Repayments of short-term borrowings

     (800 )     —    

Proceeds from exercises under share-based compensation plans, net

     26,400       33,100  

Excess tax benefit relating to share-based compensation plans

     19,300       20,800  

Purchase of common stock

     (180,800 )     (81,300 )

Dividends paid

     (30,100 )     (29,100 )
                

Net cash used in financing activities from continuing operations

     (166,000 )     (56,500 )
                

Net cash flows from discontinued operations:

    

Net cash provided by operating activities

     —         600  
                

Effect of exchange rate changes on cash and cash equivalents

     3,200       4,700  
                

(Decrease) increase in cash and cash equivalents during the period

     (60,800 )     81,300  
                

Balance at January 1

     488,400       416,200  
                

Balance at June 30

   $ 427,600     $ 497,500  
                

Supplemental cash flow information

    

Cash paid for:

    

Interest

   $ 6,000     $ 5,900  

Income taxes

   $ 85,800     $ 60,600  

Noncash transactions:

    

Acquisition costs

   $ 2,500     $ 200  

Accrued milestone payments

     —       $ 3,000  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in the company’s 2007 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in our 2007 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarters ended May 31, 2008 and May 31, 2007 and as of November 30, 2007. No events occurred related to these foreign subsidiaries during the months of June 2008, June 2007 or December 2007 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.

New Accounting Pronouncements

In September 2006, the Financial Accounting Standard Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 157, Fair Value Measurements (“FAS 157”), which defines fair value, establishes a framework for measuring fair value and expands disclosure requirements about fair value measurements. FAS 157 was effective beginning in Bard’s 2008 fiscal year, except for nonfinancial assets and liabilities measured at fair value on a non-recurring basis for which it will be effective at the beginning of Bard’s 2009 fiscal year. The impact of the adoption of FAS 157 was not material to the company’s condensed consolidated financial statements and the adoption of the items deferred until fiscal 2009 is not expected to be material.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations (“FAS 141R”) and SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (“FAS 160”). FAS 141R requires an acquirer to measure the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree at their fair value on the acquisition date, with goodwill being the excess value over the net identifiable assets acquired. FAS 160 clarifies that a noncontrolling interest in a subsidiary should be reported as equity in the consolidated financial statements. FAS 141R and FAS 160 will be effective as of the beginning of Bard’s 2009 fiscal year. The company is currently evaluating the impact of the adoption of FAS 141R and FAS 160.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133 (“FAS 161”), which requires enhanced disclosures about a company’s derivative and hedging activities. FAS 161 will be effective as of the beginning of Bard’s 2009 fiscal year. The company is currently evaluating the impact of the adoption of the enhanced disclosures required by FAS 161.

In June 2008, the FASB issued FASB Staff Position (“FSP”) EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities (“FSP EITF 03-6-1”).

 

7


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

The FSP addresses whether awards granted in share-based payment transactions are participating securities prior to vesting and therefore need to be included in the earnings allocation in computing earnings per share using the two-class method under SFAS No. 128, Earnings per Share. The FSP requires unvested share-based payment awards that have non-forfeitable rights to dividend or dividend equivalents to be treated as a separate class of securities in calculating earnings per share. FSP EITF 03-6-1 will be effective as of the beginning of Bard’s 2009 fiscal year and will be retrospectively applied to all prior-periods presented. The company is currently evaluating the impact of the adoption of the FSP on earnings per share.

2. Acquisitions and Divestitures

Business Acquisitions

On June 5, 2008, the company acquired all of the outstanding shares of Specialized Health Products International, Inc. (“Specialized Health Products”) for a purchase price of $1.00 per share in cash, totaling $68.4 million, plus direct acquisition costs of $2.3 million. Specialized Health Products manufactures and markets vascular access products, including winged infusion sets, which are used to deliver therapeutic agents through vascular access ports. The acquisition represents a strategic addition to Bard’s port franchise. The acquisition was accounted for as a business combination and the results of operations have been included in the company’s results since the acquisition date. The preliminary purchase price allocation resulted in the recognition of core technologies of $33.8 million; patents of $11.1 million; deferred tax assets of $8.9 million consisting of a net operating loss carryforward; other net assets of $12.4 million primarily consisting of cash, inventory, and accounts receivable; and deferred tax liabilities of $15.7 million primarily associated with acquired intangible assets. The acquired intangible assets will be amortized over their weighted average useful lives of approximately 12 years. The excess of the purchase price over the fair value of the assets acquired of $20.2 million was recorded as goodwill, which is not deductible for income tax purposes. The final allocation of the purchase price is expected to be completed as soon as practicable but no later than 12 months after the acquisition date.

On January 11, 2008, the company acquired the assets of the LifeStent® family of stents from Edwards Lifesciences Corporation for a net cash payment of $73.2 million, plus direct acquisition costs of $3.6 million, and up to $65.0 million in contingent milestone payments. The contingent milestone payments consist of $50.0 million related to regulatory approvals and $15.0 million related to the transfer of manufacturing operations to Bard. The acquisition represents a strategic addition to Bard’s portfolio of non-coronary stent and stent graft products that is complementary to the company’s current products, call points and technology platforms. The acquisition was accounted for as a business combination and the results of operations have been included in the company’s results since the acquisition date. The fair value of the assets acquired was approximately $105.5 million. The difference between the fair value of the assets acquired and the initial payments was recognized as an acquisition related liability. This liability will be reduced upon the payment of the contingent milestone payments with the remaining amounts to be recorded as a deferred tax asset and goodwill.

The preliminary purchase price allocation resulted in the recognition of core technologies of $52.2 million; customer relationships of $9.2 million; other assets of $14.1 million consisting primarily of inventory and equipment; an acquisition related liability of $26.8 million; and deferred tax liabilities of $16.3 million. Core technologies and customer relationships will be amortized over the estimated useful lives of 15 and 8 years, respectively. In addition, $44.4 million was allocated to purchased research and development (“R&D”), for which technological feasibility had not been established and no alternative future use existed at the acquisition date. The purchased R&D relates to the pre-market approval (“PMA”) submitted to the U.S. Food and Drug Administration (“FDA”) for use of the LifeStent® products in the superficial femoral artery. The company recorded a charge for purchased R&D in research and development expense in its condensed consolidated statements of income. In connection with the write-off of purchased R&D, the company recorded a discrete tax

 

8


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

benefit of $16.4 million. The value assigned to purchased R&D was determined based upon the present value of expected future cash flows associated with the product adjusted for the probability of product approval and discounted at a risk-adjusted rate. The ongoing activity with respect to the future development for this product is not expected to be material to the company’s research and development expense. The final allocation of the purchase price is expected to be completed as soon as practicable but no later than 12 months after the acquisition date.

Asset Disposition

On June 12, 2008, the company decided to discontinue the sale of its Salute II hernia fixation device. This decision was based on a strategic review, which considered the continued technical challenges associated with the product’s manufacturing and its overall profitability, as well as an assessment of alternative devices under development. In connection with this decision, the company recorded a non-cash charge of $40.5 million ($34.9 million after-tax). This charge consisted of the write-off of patents of $34.6 million and machinery and equipment of $2.2 million, which in total were recorded to other (income) expense, net, and inventory of $3.7 million, which was recorded to cost of goods sold.

Product Withdrawal

The company withdrew from the synthetic bulking market and discontinued sales of the Tegress product effective January 31, 2007. This withdrawal was accounted for as a discontinued operation.

Condensed financial information related to the discontinued operation was as follows:

 

     Quarter Ended
June 30, 2007
   Six Months Ended
June 30, 2007
(dollars in millions)          

Net sales

   $ —      $ 0.3
             

Income from operations

     —        0.1

Income tax provision

     —        0.1
             

Income on discontinued operations

   $ —      $ —  
             

3. Earnings per Share

The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) are as follows:

 

     Quarter Ended
June 30,
   Six Months Ended
June 30,
     2008    2007    2008    2007

Average common shares outstanding

   99,300    103,600    99,700    103,400

Dilutive share equivalents from share-based compensation plans

   3,100    3,300    3,200    3,400
                   

Average common and common equivalent shares outstanding—assuming dilution

   102,400    106,900    102,900    106,800
                   

4. Income Taxes

The company’s effective tax rate for the quarter ended June 30, 2008 increased to approximately 34% compared to approximately 30% for the same period in 2007. The increase was principally due to the discrete tax effect related to the Salute II charge resulting from the write-off of assets primarily located in a low tax

 

9


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

jurisdiction. The company’s effective tax rate for the six months ended June 30, 2008 increased to approximately 30% compared to approximately 29% for the same period in 2007. The increase was due to the tax effect related to the Salute II charge, partially offset by the discrete tax effect of purchased R&D charges primarily associated with the acquisition of the assets of the Lifestent® family of stents from Edwards Lifesciences.

As of June 30, 2008, the total amount of liability for unrecognized tax benefits was approximately $60.3 million (of which $55.8 million would impact the effective tax rate if recognized) plus approximately $13.4 million of accrued interest. As of December 31, 2007, the corresponding liability for unrecognized tax benefits was approximately $55.3 million plus approximately $11.7 million of accrued interest.

Based upon the expiration of statutes of limitations and/or the conclusion of tax examinations in several jurisdictions, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $31.0 million over the next twelve-month period. The audit of the company’s U.K. tax filing for the 2005 year concluded in the first quarter of 2008 with no adjustment by the tax authority.

5. Financial Instruments

Foreign Exchange Derivative Instruments

The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to fluctuations between certain currencies. These contracts limit volatility because gains and losses associated with exchange rate movements are generally offset by movements in the underlying hedged item.

A roll forward of the notional value of the company’s forward currency and option contracts is as follows:

 

     Forwards     Options

(dollars in millions)

    

Balance, December 31, 2007

   $ 126.5     $ —  

New contracts

     31.3       63.6

Expired/cancelled contracts

     (64.8 )     —  
              

Balance, June 30, 2008

   $ 93.0     $ 63.6
              

At June 30, 2008, the fair value of forward currency and option contracts was recorded in either other current assets or accrued expenses in the condensed consolidated balance sheet. The fair value of forward currency contracts was $(0.7) million and $(0.8) million at June 30, 2008 and December 31, 2007, respectively. The fair value of option contracts was $2.2 million at June 30, 2008. For the six months ended June 30, 2008, the company reclassified a loss of approximately $0.8 million from accumulated other comprehensive income to other income, net and cost of goods sold in the condensed consolidated statement of income as hedged intercompany balances were settled. This reclassification was net of $0.3 million of associated tax effects.

Investments

Cash equivalents consist of highly liquid investments purchased with original maturities of ninety days or less and amounted to $403.6 million and $458.0 million at June 30, 2008 and December 31, 2007, respectively.

 

10


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

Short-term investments consist of high quality corporate debt securities and commercial paper purchased with maturities of less than one year. These investments amounted to $6.7 million and $82.2 million at June 30, 2008 and December 31, 2007, respectively. There were no realized gains or losses on short-term investments reported in the six months ended June 30, 2008 and the year ended December 31, 2007. There were unrealized gains of $0.1 million on short-term investments in the six months ended June 30, 2008. There were unrealized gains of $0.3 million and unrealized losses of $0.1 million on short-term investments for the year ended December 31, 2007.

Available-for-sale equity securities recorded in other assets were approximately $1.3 million and $2.5 million at June 30, 2008 and December 31, 2007, respectively.

Fair Value of Financial Instruments

The following table summarizes the basis used to measure financial instruments at fair value:

 

      Balance at
June 30,

2008
    Quoted Prices
in Active
Markets for
Identical
Items
   Significant
Other
Observable
Inputs
 

(dollars in millions)

       

Short-term investments

   $ 6.7     $ 6.7    $ —    

Equity securities

     1.3       1.3      —    

Forward currency contracts

     (0.7 )     —        (0.7 )

Option contracts

     2.2       —        2.2  

The fair value of short-term investments and equity securities was measured using quoted prices in active markets for identical items and is valued using published market prices unadjusted for transaction costs. The fair value of forward currency and option contracts was measured using significant other observable inputs and is valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each contract.

6. Inventories

The following is a summary of inventories:

 

     June 30,
2008
   December 31,
2007

(dollars in millions)

  

Finished goods

   $ 168.5    $ 143.6

Work in process

     28.8      21.9

Raw materials

     86.0      79.2
             
   $ 283.3    $ 244.7
             

7. Contingencies

In the ordinary course of business, the company is subject to various legal proceedings and claims, including, for example, product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute

 

11


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

one or more products. If a patent owned by or licensed to the company were to be determined to be invalid or unenforceable, the company might be required to reduce the value of the patent on the company’s balance sheet and to record a corresponding charge, which could be significant in amount.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for any remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined.

The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial position or liquidity. However, one or more of the proceedings could be material to the company’s business and results of operations for a future period.

On November 27, 2006, the company’s Urological Division received a subpoena issued by the Department of Health and Human Services, Office of Inspector General, under the authority of the federal healthcare fraud and false claims statutes. The subpoena seeks documents related to the division’s brachytherapy business. The company is cooperating with the government’s request and is in the process of responding to the subpoena. At this stage of the inquiry, the likelihood of an adverse outcome cannot be assessed. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period.

As of July 25, 2008, approximately 735 federal and 1,100 state lawsuits involving individual claims by approximately 1,940 plaintiffs, as well as three putative class actions, have been filed or asserted against the company with respect to its Composix® Kugel® product intended for ventral hernia repair (collectively, the “Composix Claims”). One class action lawsuit consolidates eight previously-filed class action lawsuits. The company voluntarily recalled certain sizes and lots of the product beginning in December 2005. The actions generally seek damages for personal injury resulting from use of the product. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. On June 22, 2007, the Judicial Panel on Multidistrict Litigation transferred Composix lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. Approximately 1,075 of the state lawsuits, involving individual claims by approximately 1,090 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. In March 2008, the Superior Court of the State of Rhode Island directed that certain lawsuits had improperly consolidated numerous plaintiffs and ordered the re-filing of complaints on behalf of those plaintiffs, resulting in an increase in the number of lawsuits but a decrease in the number of plaintiffs in lawsuits pending in that court.

The Composix Claims are at a preliminary stage. In the vast majority of these cases, we have not yet obtained and reviewed complete information regarding the plaintiffs and their medical conditions, and

 

12


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

consequently, we are unable to fully evaluate the claims or determine the time frame in which they may be resolved. As in most litigation of this nature, the Composix Claims present a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. We believe that many settlements and judgments relating to the Composix Claims may be covered in whole or in part under our product liability insurance policies. While the company intends to vigorously defend the Composix Claims, it cannot give any assurances that the Composix Claims will not have a material adverse impact on the company’s result of operations in future periods or the company’s financial position or liquidity.

On February 21, 2007, Southeast Missouri Hospital filed a putative class action complaint on behalf of itself and all others similarly situated against the company and another manufacturer under the caption Southeast Missouri Hospital, et al. v. C. R. Bard, Inc., et al. (Civil Action No. 1:07-cv-00031, United States District Court, Eastern District of Missouri, Southeastern District). The complaint was later amended to add St. Francis Medical Center as an additional named plaintiff. Co-defendant Tyco International, Inc.’s motion to dismiss was granted and consequently Tyco is no longer a party to the action. The plaintiffs allege that the company conspired to exclude competitors from the market and that the company sought to maintain market share by engaging in conduct in violation of state and federal antitrust laws. The plaintiff seeks injunctive relief and money damages. Antitrust damages are subject to trebling. The company intends to defend this matter vigorously. At this time, it is not possible to assess the likelihood of an adverse outcome or determine an estimate, or a range of estimates, of potential damages. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period or the company’s financial position or liquidity.

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135. The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the court is currently assessing Gore’s assertion that the patent is unenforceable due to inequitable conduct. Because the company considers this matter a gain contingency, no amounts have been recorded as of June 30, 2008.

 

8. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2003 Long Term Incentive Plan of C. R. Bard, Inc. (the “2003 Plan”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc. (the “Directors’ Plan”) to certain directors, officers and employees. The total number of remaining shares at June 30, 2008 that may be issued under the 2003 Plan was 4,359,077 and under the Directors’ Plan was 105,566. Shares remaining for issuance under the 2003 Plan include 2,225,000 shares authorized by the shareholders at the company’s Annual Meeting of Shareholders on April 16, 2008. Awards under the 2003 Plan may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company has two employee share purchase programs.

Amounts recognized for share-based compensation are as follows:

 

     Quarter Ended
June 30,
    Six Months Ended
June 30,
 
          2008             2007             2008             2007      
(dollars in millions)             

Total cost of share-based compensation plans

   $ 9.2     $ 10.6     $ 19.6     $ 22.7  

Amounts capitalized in inventory and fixed assets

     (0.3 )     (0.4 )     (0.6 )     (0.8 )

Amounts recognized in income for amounts previously capitalized in inventory and fixed assets

     0.4       0.4       0.7       0.8  
                                

Amounts charged against income

   $ 9.3     $ 10.6     $ 19.7     $ 22.7  
                                

 

13


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

As of June 30, 2008, there were approximately $62.5 million of unrecognized compensation costs related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately three years. The company repurchases shares, from time to time, on the open market to satisfy share-based payment arrangements. The company has sufficient treasury shares to satisfy expected share-based payment arrangements for the remainder of the year.

9. Pension and Other Postretirement Benefit Plans

Defined Benefit Pension Plans - The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans that together cover substantially all domestic and certain foreign employees. These plans provide benefits based upon a participant’s compensation and years of service. The components of net periodic pension expense are as follows:

 

     Quarter Ended June 30,  
     2008     2007  
(dollars in millions)    Tax
Qualified
Plans
    Nonqualified
Plans
       Total         Tax
Qualified
Plans
    Nonqualified
Plans
       Total      

Service cost net of employee contributions

   $ 4.0     $ 0.6    $ 4.6     $ 3.8     $ 0.6    $ 4.4  

Interest cost

     3.7       0.6      4.3       3.2       0.5      3.7  

Expected return on plan assets

     (4.9 )     —        (4.9 )     (4.3 )     —        (4.3 )

Amortization

     0.9       0.2      1.1       1.3       0.1      1.4  
                                              

Net periodic pension expense

   $ 3.7     $ 1.4    $ 5.1     $ 4.0     $ 1.2    $ 5.2  
                                              

 

     Six Months Ended June 30,  
     2008     2007  
(dollars in millions)    Tax
Qualified
Plans
    Nonqualified
Plans
       Total         Tax
Qualified
Plans
    Nonqualified
Plans
       Total      

Service cost net of employee contributions

   $ 8.0     $ 1.3    $ 9.3     $ 7.6     $ 1.2    $ 8.8  

Interest cost

     7.4       1.3      8.7       6.4       1.0      7.4  

Expected return on plan assets

     (9.9 )     —        (9.9 )     (8.6 )     —        (8.6 )

Amortization

     1.8       0.2      2.0       2.6       0.2      2.8  
                                              

Net periodic pension expense

   $ 7.3     $ 2.8    $ 10.1     $ 8.0     $ 2.4    $ 10.4  
                                              

Other Postretirement Benefit Plans - The company does not provide subsidized postretirement healthcare benefits and life insurance coverage except to a limited number of former employees. As this plan is unfunded, contributions are made as benefits are incurred. The net periodic benefit expense was $0.2 million for each of the quarters ended June 30, 2008 and 2007. The net periodic benefit expense was $0.5 million for each of the six month periods ended June 30, 2008 and 2007.

Employer Contributions to Defined Benefit Plans - For the six months ended June 30, 2008 and 2007, the company made no required or voluntary contributions to its U.S. tax-qualified plan. For the six months ended June 30, 2008 and 2007, the company made voluntary contributions of $1.1 million and $5.0 million, respectively, to the company’s non-U.S. tax-qualified plans.

 

14


Table of Contents

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

10. Segment Information

The company’s management considers its business to be a single segment entity—the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices that are purchased by hospitals, physicians and nursing homes, many of which are used once and discarded. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis. The company’s chief operating decision makers generally evaluate profitability and associated investment on an enterprise-wide basis due to shared infrastructures. The following table represents net sales by geographic region based on the location of the external customer:

 

     Quarter Ended
June 30,
   Six Months Ended
June 30
     2008    2007    2008    2007
(dollars in millions)               

United States

   $ 406.3    $ 374.8    $ 805.5    $ 748.7

Europe

     136.8      105.1     
253.9
     199.7

Japan

     30.1      28.1     
58.1
     54.5

Rest of world

     43.9      37.7     
83.6
     71.0
                           
   $ 617.1    $ 545.7    $ 1,201.1    $ 1,073.9
                           

Income from continuing operations before income taxes

   $ 118.9    $ 139.3    $ 223.7    $ 281.7
                           

Depreciation

   $ 13.2    $ 12.5    $ 25.7    $ 24.3
                           

Amortization

   $ 9.9    $ 7.5    $ 19.3    $ 14.5
                           

The following table represents net sales by disease state management:

 

     Quarter Ended
June 30,
   Six Months Ended
June 30,
     2008    2007    2008    2007
(dollars in millions)               

Vascular

   $ 163.6    $ 135.9    $ 314.0    $
263.6

Urology

     176.4      160.9      345.1      316.1

Oncology

     163.7      141.9      313.7     
269.7

Surgical Specialties

     88.9      86.5      181.9     
183.6

Other products

     24.5      20.5      46.4     
40.9
                           
   $ 617.1    $ 545.7    $ 1,201.1    $
1,073.9
                           

 

15


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Overview

The company designs, manufacturers, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad, diversified portfolio of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities in the United States and abroad, principally in Europe and Japan. In general, the company’s products are intended to be used once and then discarded or implanted either temporarily or permanently. The company reports sales in four major product group categories: vascular, urology, oncology and surgical specialties. The company also has a product group of other products.

The company’s earnings are driven by its ability to continue to generate sales of its products and improve operating efficiency. Bard’s ability to increase sales over time depends upon its success in developing, acquiring and marketing innovative and differentiated products that meet the needs of clinicians and their patients. For the six months ended June 30, 2008, the company spent $124.0 million on research and development (“R&D”), including purchased R&D. The company expects R&D spending, excluding purchased R&D, to continue to increase in the future. The company also makes selective acquisitions of businesses, products and technologies, generally focusing on small to medium sized transactions to provide ongoing growth opportunities. In addition, the company may from time to time consider acquisitions of larger, established companies under appropriate circumstances. The company may also periodically divest lines of business in which it is not able to reasonably attain or maintain a leadership position or for other strategic reasons.

Recent Developments

On June 12, 2008, the company decided to discontinue the sale of its Salute II hernia fixation device. This decision was based on a strategic review, which considered the continued technical challenges associated with the product’s manufacturing and its overall profitability, as well as an assessment of alternative devices under development. In connection with this decision, the company recorded a non-cash charge of $40.5 million ($34.9 million after-tax).

On June 5, 2008, the company acquired all of the outstanding shares of Specialized Health Products International, Inc. (“Specialized Health Products”) for a purchase price of $1.00 per share in cash, totaling $68.4 million, plus direct acquisition costs of $2.3 million. Specialized Health Products manufactures and markets vascular access products, including winged infusion sets, which are used to deliver therapeutic agents through vascular access ports. The acquisition represents a strategic addition to Bard’s port franchise.

On January 11, 2008, the company acquired the assets of the LifeStent® family of stents from Edwards Lifesciences Corporation (“Edwards Lifesciences”) for a net cash payment of $73.2 million, plus direct acquisition costs of $3.6 million, and up to $65.0 million in contingent milestone payments. The acquisition represents a strategic addition to Bard’s portfolio of non-coronary stent and stent graft products that is complementary to our current products, call points and technology platforms.

See Note 2 of the Notes to Condensed Consolidated Financial Statements for additional discussion of the acquisitions and the divestiture.

 

16


Table of Contents

Results of Operations

Net Sales

Bard reported consolidated net sales for the quarter ended June 30, 2008 of $617.1 million, an increase of 13% on a reported basis (10% on a constant currency basis) over the quarter ended June 30, 2007 consolidated net sales of $545.7 million. Bard reported consolidated net sales for the six months ended June 30, 2008 of $1,201.1 million, an increase of 12% on a reported basis (9% on a constant currency basis) over the six months ended June 30, 2007 consolidated net sales of $1,073.9 million. Net sales “on a constant currency basis” is a non-GAAP financial measure and should not be viewed as a replacement of GAAP results. See “Management’s Use of Non-GAAP Measures” below.

Price changes had the effect of increasing consolidated net sales for the quarter ended June 30, 2008 by 0.1% compared to the same period in the prior year. Exchange rate fluctuations had the effect of increasing consolidated net sales for the quarter ended June 30, 2008 by approximately 3% as compared to the same period in the prior year. Price changes had the effect of decreasing consolidated net sales for the six months ended June 30, 2008 by 0.1% compared to the same period in the prior year. Exchange rate fluctuations had the effect of increasing consolidated net sales for the six months ended June 30, 2008 by 3% as compared to the same period in the prior year. The primary exchange rate movement that impacts net sales is the movement of the Euro compared to the U.S. dollar. The impact of exchange rate movements on net sales is not indicative of the impact on net earnings due to the offsetting impact of exchange rate movements on operating costs and expenses, costs incurred in other currencies and the company’s hedging activities.

U.S. net sales in the quarter ended June 30, 2008 of $406.3 million increased 8% compared to $374.8 million in the prior year quarter. International net sales in the quarter ended June 30, 2008 of $210.8 million increased 23% on a reported basis (13% on a constant currency basis) compared to $170.9 million in the prior year quarter. U.S. net sales for the six months ended June 30, 2008 of $805.5 million increased 8% compared to $748.7 million in the prior year period. International sales for the six months ended June 30, 2008 of $395.6 million increased 22% on a reported basis (12% on a constant currency basis) compared to $352.2 million in the prior year period.

Presented below is a discussion of consolidated net sales by disease state for the quarters and six months ended June 30, 2008 and 2007, respectively:

Product Group Summary of Net Sales

 

     Quarter Ended June 30,     Six Months Ended June 30,  
(dollars in millions)    2008    2007    Change     Constant
Currency
    2008    2007    Change     Constant
Currency
 

Vascular

   $ 163.6    $ 135.9    20 %   14 %   $ 314.0    $ 263.6    19 %   14 %

Urology

     176.4      160.9    10 %   8 %     345.1      316.1    9 %   7 %

Oncology

     163.7      141.9    15 %   13 %     313.7      269.7    16 %   14 %

Surgical Specialties

     88.9      86.5    3 %   —         181.9      183.6    (1) %   (3) %

Other

     24.5      20.5    20 %   18 %     46.4      40.9    13 %   12 %
                                                    
   $ 617.1    $ 545.7    13 %   10 %   $ 1,201.1    $ 1,073.9    12 %   9 %
                                                    

 

17


Table of Contents

Vascular Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products, electrophysiology products and surgical graft products. Consolidated net sales for the quarter ended June 30, 2008 of vascular products increased 20% on a reported basis (14% on a constant currency basis) compared to the prior year quarter. U.S. net sales for the quarter ended June 30, 2008 of vascular products grew 12% compared to the prior year quarter. International net sales for the quarter ended June 30, 2008 increased 31% on a reported basis (17% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of vascular products increased 19% on a reported basis (14% on a constant currency basis) compared to the same period in the prior year. U.S. net sales for the six months ended June 30, 2008 of vascular products grew 9% compared to the same period in the prior year. International net sales for the six months ended June 30, 2008 increased 31% on a reported basis (19% on a constant currency basis) compared to the same period in the prior year. The vascular group is the company’s most global business, with international net sales comprising 49% and 46% of consolidated net sales of vascular products for the quarters ended June 30, 2008 and 2007, respectively.

Consolidated net sales for the quarter ended June 30, 2008 of endovascular products increased 27% on a reported basis (21% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of endovascular products increased 24% on a reported basis (19% on a constant currency basis) compared to the same period in the prior year. The company’s percutaneous transluminal angioplasty balloon catheters, vena cava filters, stents, including the LifeStent® family of stents, and biopsy products contributed to the growth in this category for the quarter and six months ended June 30, 2008.

Consolidated net sales for the quarter ended June 30, 2008 of electrophysiology products increased 19% on a reported basis (12% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of electrophysiology products increased 23% on a reported basis (16% on a constant currency basis) compared to the same period in the prior year. The company’s steerable diagnostic catheter line contributed to the growth in this category for the quarter and six months ended June 30, 2008.

Consolidated net sales for the quarter ended June 30, 2008 of surgical graft products were flat on a reported basis (decreased 5% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of surgical graft products decreased 2% on a reported basis (6% on a constant currency basis) compared to the same period in the prior year.

Urology Products - Bard markets a wide range of products for the urology market, including basic drainage products, continence products and urological specialty products. Bard also markets the StatLock® stabilization device products, which are used to secure many types of catheters sold by Bard and other companies.

 

18


Table of Contents

Consolidated net sales for the quarter ended June 30, 2008 of urology products increased 10% on a reported basis (8% on a constant currency basis) compared to the prior year quarter. U.S. net sales of urology products for the quarter ended June 30, 2008 grew 7% compared to the prior year quarter. International net sales for the quarter ended June 30, 2008 of urology products increased 17% on a reported basis (10% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of urology products increased 9% on a reported basis (7% on a constant currency basis) compared to the same period in the prior year. U.S. net sales of urology products represented 71% of consolidated net sales of urology products for the six months ended June 30, 2008 and grew 8% compared to the same period in the prior year. International net sales for the six months ended June 30, 2008 of urology products increased 12% on a reported basis (6% on a constant currency basis) compared to the same period in the prior year.

Basic drainage products represent the core of the company’s urology business. Consolidated net sales for the quarter ended June 30, 2008 of basic drainage products increased 10% on a reported basis (9% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the quarter ended June 30, 2008 of infection control Foley catheter products grew 18% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of basic drainage products increased 9% on a reported basis (8% on a constant currency basis) compared to the same period in the prior year. Consolidated net sales for the six months ended June 30, 2008 of infection control Foley catheters grew 16% on both a reported basis and constant currency basis compared to the same period in the prior year.

Consolidated net sales for the quarter ended June 30, 2008 of urological specialty products, which include brachytherapy products and services, decreased 3% on a reported basis (6% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of urological specialty products decreased 3% on a reported basis (6% on a constant currency basis) compared to the same period in the prior year. The decrease in sales of urological specialty products was primarily driven by a decline in brachytherapy sales. The company believes that the brachytherapy market has been losing procedural share to alternative therapies, a trend that may continue.

Consolidated net sales for the quarter ended June 30, 2008 of continence products increased 14% on a reported basis (12% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of continence products increased 12% on a reported basis (10% on a constant currency basis) compared to the same period in the prior year. The company’s pelvic floor reconstruction product line and surgical slings were the primary growth drivers in the continence category for the quarter and six months ended June 30, 2008.

Consolidated net sales for the quarter ended June 30, 2008 of the Statlock® stabilization device product line increased 24% on a reported basis (23% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of Statlock® stabilization device product line increased 30% on a reported basis (29% on a constant currency basis) compared to the same period in the prior year.

Oncology Products - The company’s oncology products include specialty access products used primarily for chemotherapy. Consolidated net sales for the quarter ended June 30, 2008 of oncology products grew 15% on a reported basis (13% on a constant currency basis) compared to the prior year quarter. U.S. net sales represented 74% of consolidated net sales of oncology products for the quarter ended June 30, 2008 and grew 12% compared to the prior year quarter. International net sales for the quarter ended June 30, 2008 of oncology products grew 26% on a reported basis (15% on a constant currency basis) compared to the prior year quarter. Consolidated net

 

19


Table of Contents

sales for the six months ended June 30, 2008 of oncology products increased 16% on a reported basis (14% on a constant currency basis) compared to the same period in the prior year. U.S. net sales for the six months ended June 30, 2008 of oncology products grew 15% compared to the same period in the prior year. International net sales for the six months ended June 30, 2008 of oncology products grew 22% on a reported basis (12% on a constant currency basis) compared to the same period in the prior year. The company’s specialty access ports, peripherally inserted central catheters (“PICCs”) and vascular access ultrasound devices were the primary contributors to the growth in the oncology category for the quarter and six months ended June 30, 2008.

Surgical Specialty Products - Surgical specialty products include soft tissue repair, performance irrigation and hemostasis product lines. Consolidated net sales for the quarter ended June 30, 2008 of surgical specialty products increased 3% on a reported basis (flat on a constant currency basis) compared to the prior year quarter. U.S. net sales for the quarter ended June 30, 2008 of surgical specialty products decreased 1% compared to the prior year quarter. International net sales for the quarter ended June 30, 2008 of surgical specialty products increased 13% on a reported basis (3% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of surgical specialty products decreased 1% on a reported basis (3% on a constant currency basis) compared to the same period in the prior year. U.S. net sales for the six months ended June 30, 2008 of surgical specialty products decreased 7% compared to the same period in the prior year. International net sales for the six months ended June 30, 2008 of surgical specialty products grew 16% on a reported basis (6% on a constant currency basis) compared to the same period in the prior year.

Consolidated net sales for the quarter ended June 30, 2008 of the company’s soft tissue repair product line, which includes core hernia repair and hernia fixation products, were flat on a reported basis (decreased 3% on a constant currency basis) compared to the prior year quarter. Consolidated net sales for the six months ended June 30, 2008 of the company’s soft tissue repair product line decreased 2% on a reported basis (5% on a constant currency basis) compared to the prior year period due primarily to: (i) a hold on the manufacture and the subsequent discontinuance of the sale of the company’s Salute II hernia fixation device; and (ii) a decline in sales in the United States of the company’s core hernia repair products. The trend in the soft tissue repair product line may continue.

On December 29, 2005, the company initiated a voluntary Class I product recall of its Bard® Composix® Kugel® Mesh X-Large Patch intended for ventral hernia repair. Following the recall, the U.S. Food and Drug Administration (“FDA”) conducted an inspection and issued a Form-483 notice to the company’s Davol, Inc. subsidiary identifying certain observations. The company has addressed these observations.

On March 15, 2006, the company voluntarily expanded the December 2005 recall to include certain manufacturing lots of the large Composix® Kugel® patch and large Composix® circle. In December 2006, the company decided to voluntarily expand the March 2006 recall to include additional manufacturing lots and initiated the expanded recall on January 10, 2007.

Following the expanded recall, the FDA conducted a follow-up inspection and issued a Form-483 notice to Davol identifying certain observations regarding Davol’s quality systems. The company has responded and is in the process of addressing these observations. On April 25, 2007, Davol received a Warning Letter from the New England District Office of the FDA resulting from the follow-up inspection. The Warning Letter relates specifically to non-conformances in Davol’s quality systems previously identified in the related Form-483 notice. The Warning Letter states that, until Davol resolves the outstanding issues covered by the Warning Letter, no premarket submissions for Class III devices to which the non-conformances are reasonably related will be cleared or approved. Davol presently has no such submissions before the FDA. The company has responded to all observations in the Warning Letter and intends to fully implement corrective actions to address the FDA’s concerns. The company has met with FDA representatives to advise them of the progress being made in addressing observations in the Warning Letter and has proposed a re-inspection of the Davol facility which the company expects to occur in the second half of 2008. The company cannot, however, give any assurances that the FDA will be satisfied with its response to the Warning Letter or as to the expected date of resolution of matters included in the Warning Letter.

 

20


Table of Contents

On February 13, 2008, the FDA issued a Form-483 notice to the company in connection with an inspection of the company’s manufacturing facility located in Humacao, Puerto Rico. The Form-483 notice identified certain observations regarding the facility’s quality system. The facility manufactures products for many of the company’s divisions and subsidiaries, including soft tissue repair products for the company’s Davol subsidiary. The company has responded to the FDA and is in the process of addressing these observations. On July 28, 2008, the company received a Warning Letter from the San Juan District office of the FDA. The Warning Letter relates specifically to non-conformances in quality systems previously identified in the related Form-483 notice. The Warning Letter states that, until the company resolves the outstanding issues covered by the Warning Letter, no premarket submissions for Class III devices to which the non-conformances are reasonably related will be cleared or approved. The company presently has no such submissions before the FDA. The company intends to fully implement corrective actions to address the concerns identified in the Warning Letter. However, the company cannot give any assurances that the FDA will be satisfied with its response to the Warning Letter or as to the expected date of resolution of matters included in the Warning Letter.

Other Products - The other product group includes irrigation, wound drainage and certain original equipment manufacturers’ products. Consolidated net sales of other products for the quarter ended June 30, 2008 were $24.5 million, an increase of 20% on a reported basis (18% on a constant currency basis) compared to the prior year quarter.
Consolidated net sales of other products for the six months ended June 30, 2008 increased 13% on a reported basis (12% on a constant currency basis) compared to the same period in the prior year.

Costs and Expenses

The following is a summary of major costs and expenses as a percentage of net sales for the quarters and six months ended June 30, 2008 and 2007, respectively:

 

    Quarter Ended
June 30,
    Six Months Ended
June 30,
 
        2008             2007             2008             2007      

Cost of goods sold

  39.5 %   39.7  %   39.1 %   39.4 %

Marketing, selling and administrative expense

  29.3 %   29.4  %   29.1 %   29.3 %

Research and development expense

  6.2 %   6.4  %   10.3 %   6.1 %

Interest expense

  0.5 %   0.5  %   0.5 %   0.5 %

Other (income) expense, net

  5.2 %   (1.6 )%   2.4 %   (1.5 )%
                       

Total costs and expenses

  80.7 %   74.4  %   81.4 %   73.8 %
                       

Cost of goods sold - Cost of goods sold consists principally of the manufacturing and distribution costs of the company’s products as well as royalties and the amortization of intangible assets. The impact of incremental amortization of intangible assets acquired in the past 12 months increased cost of goods sold over the prior year quarter and six month period in each case by approximately 40 basis points. Reductions in cost of goods sold were attributed primarily to cost improvements, which offset the impact of incremental amortization of intangible assets.

Marketing, selling and administrative expense - Marketing, selling and administrative expense consists principally of the costs associated with the company’s sales and administrative organizations. The company’s marketing, selling and administrative expense as a percentage of net sales for the quarter and six months ended June 30, 2008 was 29.3% and 29.1%, respectively, a decrease of 10 basis points and 20 basis points, respectively, compared to the prior year periods.

Research and development expense - Research and development expense consists of expenses related to internal research and development activities, milestone payments for third-party research and development activities and purchased R&D costs arising from the company’s business development activities. Purchased R&D payments may impact the comparability of the company’s results of operations between periods. All research and development costs are expensed as incurred. For the quarter ended June 30, 2008, the company spent

 

21


Table of Contents

approximately $38.2 million on research and development activities compared to $35.1 million in the prior year quarter. For the six months ended June 30, 2008, the company spent approximately $124.0 million on research and development activities compared to $65.2 million in the prior year period. Included in the research and development costs for the six months ended June 30, 2008 was purchased R&D of approximately $49.3 million primarily associated with the acquisition of the LifeStent® family of stents from Edwards Lifesciences.

Interest expense - Interest expense for the quarter ended June 30, 2008 of $3.0 million was unchanged from the prior year quarter and reflected constant debt levels. Interest expense for the six months ended June 30, 2008 increased slightly to $6.0 million from $5.9 million for the six months ended June 30, 2007.

Other (income) expense, net - The table below presents the components of other (income) expense, net for the quarter and six months ended June 30, 2008 and 2007, respectively:

 

    Quarter Ended
June 30,
    Six Months Ended
June 30,
 
(dollars in millions)       2008             2007             2008             2007      

Interest income

  $ (4.2 )   $ (8.2 )   $ (9.8 )   $ (15.3 )

Foreign exchange (gains) losses

    —         (0.5 )     1.0       (0.7 )

Asset disposition

    36.8       —         36.8       —    

Other, net

    —         (0.1 )     0.6       (0.2 )
                               
  $ 32.6     $ (8.8 )   $ 28.6     $ (16.2 )
                               

Interest income - For the quarter ended June 30, 2008, interest income was approximately $4.2 million, compared to approximately $8.2 million for the prior year quarter. For the six months ended June 30, 2008, interest income was approximately $9.8 million, compared to $15.3 million for the six months ended June 30, 2007. The decrease for these periods was primarily due to lower balances of cash and cash equivalents and lower interest rates.

Asset disposition - For the quarter and six months ended June 30, 2008, the amount reflects a non-cash charge related to the write-off of certain assets related to the company’s decision to discontinue the sale of the Salute II hernia fixation device. See Note 2 of the Notes to Condensed Consolidated Financial Statements.

Income tax provision

The company’s effective tax rate for the quarter ended June 30, 2008 increased to approximately 34% compared to approximately 30% for the same period in 2007. The increase was principally due to the discrete tax effect related to the Salute II charge resulting from the write-off of assets primarily located in a low tax jurisdiction. The company’s effective tax rate for the six months ended June 30, 2008 increased to approximately 30% compared to approximately 29% for the same period in 2007. The increase was due to the tax effect related to the Salute II charge, partially offset by the discrete tax effect of the purchased R&D charges primarily associated with the acquisition of the assets of the Lifestent® family of stents from Edwards Lifesciences.

Net Income and Earnings Per Share

Net income and diluted earnings per share for the second quarter of 2008 were $77.9 million and $0.76, respectively. Net income and diluted earnings per share for the prior year quarter were $97.5 million and $0.91, respectively. Net income and diluted earnings per share for the six months ended June 30, 2008 were $155.9 million and $1.52, respectively. Net income and diluted earnings per share for the six months ended June 30, 2007 were $199.1 million and $1.86, respectively. The current periods reflect a non-cash charge for the write off of assets related to the Salute II hernia fixation device of $34.9 million after-tax, or $0.34 per share. The current year six month period also reflects after-tax purchased R&D charges of $31.1 million, or $0.30 per share, primarily associated with the acquisition of the assets of the Lifestent® family of stents from Edwards Lifesciences.

Liquidity and Capital Resources

The company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. Significant factors affecting the management of liquidity are cash flows generated from operating activities, capital expenditures, acquisitions of businesses and technologies, cash dividends and

 

22


Table of Contents

common stock repurchases. Cash provided from operations continues to be the company’s primary source of funds. Should it be necessary, the company believes it could borrow adequate funds at competitive terms. The company believes that its overall financial strength gives the company sufficient financing flexibility. The table below summarizes certain liquidity measures for Bard as of June 30, 2008 and 2007, respectively:

 

     2008    2007
(dollars in millions)          

Working capital

   $ 933.2    $ 1,036.7
             

Current ratio

     4.26/1      5.30/1
             

For the six months ended June 30, 2008, the company generated $204.9 million in cash flow from continuing operations, $32.8 million less than the $237.7 million generated in the prior year period. The change in current liabilities of $26.7 million, which reflected decreases in accrued expenses and income taxes payable, contributed to the decline in cash flows from continuing operations.

For the six months ended June 30, 2008, the company used $102.9 million in cash for investing activities from continuing operations, $2.3 million less than the $105.2 million used in the prior year period. In 2008, the company paid $75.2 million for the purchase of the assets of the LifeStent® family of stents from Edwards Lifesciences which included direct acquisition costs paid as of June 30, 2008. In addition, the company paid $65.4 million, for the purchase of Specialized Health Products which included direct acquisition costs paid as of June 30, 2008. In the prior year, the company paid $33.7 million to acquire the assets of Inrad, Inc.’s biopsy marker business. Net cash provided by the change in short-term investments, net in the quarter was $75.5 million compared with net cash used of $21.6 million in the prior year period. Capital expenditures were approximately $24.0 million and $25.2 million for the six months ended June 30, 2008 and 2007, respectively.

For the six months ended June 30, 2008, the company used $166.0 million in cash for financing activities from continuing operations, $109.5 million more than the $56.5 million used in the prior year period. Total debt was $149.8 million and $150.6 million at June 30, 2008 and December 31, 2007, respectively. Total debt to total capitalization was 7.3% and 7.5% at June 30, 2008 and December 31, 2007, respectively. The company spent approximately $180.8 million to repurchase 1,868,492 shares of common stock in the six months ended June 30, 2008 compared with approximately $81.3 million to repurchase 980,000 shares of common stock in the prior year period. At June 30, 2008, a total of $195.2 million remained under the company’s $500 million share repurchase authorization approved by the Board of Directors in 2007. The company paid cash dividends of $0.30 per share and $0.28 per share for the six months ended June 30, 2008 and 2007, respectively.

The company maintains a domestic syndicated bank credit facility with a $400 million five-year credit agreement that expires in June 2012. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. There were no outstanding borrowings or commercial paper borrowings at June 30, 2008 and December 31, 2007. In addition, a wholly owned foreign subsidiary of the company maintains a $250 million syndicated bank credit facility to be used for general corporate needs. Loans under the facility bear interest at the company’s option at a fixed spread to LIBOR or the higher of prime rate and 0.50% over the federal funds rate. The facility expires in October 2008. There were no outstanding borrowings under the facility at June 30, 2008 and December 31, 2007.

Contingencies

In the ordinary course of business, the company is subject to various legal proceedings and claims, including product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. See Note 7 of the Notes to Condensed Consolidated Financial Statements.

 

23


Table of Contents

Management’s Use of Non-GAAP Measures

Net sales “on a constant currency basis” is a non-GAAP financial measure. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by translating the prior year’s local currency sales by the current period’s exchange rate. Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP financial measures are intended to supplement the applicable GAAP disclosures and should not be viewed as a replacement of GAAP results.

Critical Accounting Policies

The preparation of financial statements requires the company’s management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in the company’s 2007 Annual Report on Form 10-K. There have been no significant changes to the company’s critical accounting policies since December 31, 2007.

Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information

Certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “forecast,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to product approvals, future performance of current and anticipated products, sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. The company’s forward-looking statements speak only as of the date of this report or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

In addition, there are substantial risks inherent in the medical device business. The company’s business involves the design, development, manufacture, packaging, distribution and sale of life-sustaining medical devices. These devices are often utilized on, or permanently or temporarily implanted in, patients in clinically demanding circumstances, such as operating rooms, emergency units, intensive care and critical care settings, among others. These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims (including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings) and other litigation, product withdrawals, Warning Letters, recalls, field corrections or regulatory enforcement actions relating to one or more of the company’s products, any of which could have a material adverse effect on our business, financial position, liquidity and results of operations. For further discussion of risks applicable to our business, see “Risk Factors” in the company’s 2007 Annual Report on Form 10-K.

Because actual results are affected by these and other risks and uncertainties, the company cautions investors that actual results may differ materially from those expressed or implied. It is not possible to predict or identify all risks and uncertainties, but the most significant factors, in addition to those addressed above, that

 

24


Table of Contents

could adversely affect our business or cause the actual results to differ materially from those expressed or implied include, but are not limited to:

Effective management of and reaction to risks involved in our business, including:

 

   

the ability to achieve manufacturing or administrative efficiencies, including gross margin benefits from our manufacturing process and supply chain programs or in connection with the integration of acquired businesses;

 

   

the effects of negative publicity concerning our products, which could result in product withdrawals or decreased product demand and which could reduce market or governmental acceptance of our products;

 

   

the ability to identify appropriate companies, businesses and technologies as potential acquisition candidates, to consummate and integrate such transactions or to obtain agreements for such transactions with favorable terms;

 

   

the reduction in the number of procedures using our devices caused by customers’ cost-containment pressures or preferences for alternate therapies;

 

   

the ability to maintain or increase research and development expenditures;

 

   

the uncertainty of whether increased research and development expenditures and sales force expansion will result in increased sales;

 

   

the ability to maintain our effective tax rate and uncertainty related to tax audits, appeals and litigation;

 

   

internal factors, such as retention of key employees, including sales force employees;

 

   

the ability to achieve earnings forecasts, which are generated based, among other things, on projected volumes and sales of many product types, some of which are more profitable than others;

 

   

changes in factors and assumptions employed in the application of SFAS No. 123R, Share-Based Payment, or actual results that differ from our assumptions on stock valuation and employee stock option exercise patterns, which could cause compensation expense recorded in future periods to differ significantly from the compensation expense recorded in the current period and, as a result, materially impact the company’s results of operations;

 

   

damage to any company facility, which could render the company unable to manufacture one or more products (as the company may utilize only one manufacturing facility for certain of its major products) and may require the company to reduce the output of products at the damaged facility thereby making it difficult to meet product shipping targets;

 

   

the potential impairment of goodwill and intangible assets of the company resulting from insufficient cash flow generated from such assets specifically, or our business more broadly, so as to not allow the company to justify the carrying value of the assets; and

 

   

the ability to obtain appropriate levels of product liability insurance on reasonable terms.

Competitive factors, including:

 

   

the trend of consolidation in the medical device industry as well as among our customers, resulting in potentially greater pricing pressures and more significant and complex contracts than in the past, both in the United States and abroad;

 

   

development of new products or technologies by competitors having superior performance compared to our current products or products under development which could negatively impact sales of our products or render one or more of our products obsolete;

 

   

technological advances, patents and registrations obtained by competitors that would have the effect of excluding the company from new market segments or preventing the company from selling a product or including key features in the company’s products;

 

25


Table of Contents
   

attempts by competitors to gain market share through aggressive marketing programs; and

 

   

reprocessing by third-party reprocessors of our products designed and labeled for single use.

Difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, including:

 

   

the ability to complete planned clinical trials successfully, to develop and obtain regulatory approval for products on a timely basis and to launch products on a timely basis within cost estimates;

 

   

lengthy and costly regulatory approval processes, which may result in lost market opportunities;

 

   

delays or denials of, or grants of low or reduced levels of reimbursement for, procedures using newly developed products;

 

   

the suspension or revocation of authority to manufacture, market or distribute existing products;

 

   

the imposition of additional or different regulatory requirements, such as those affecting manufacturing and labeling;

 

   

performance, efficacy or safety concerns for existing products, whether scientifically justified or not, that may lead to product discontinuations, product withdrawals, recalls, field corrections, regulatory enforcement actions, litigation or declining sales, including adverse events relating to the company’s vena cava filters and hernia repair products;

 

   

FDA inspections resulting in Form-483 notices and/or Warning Letters identifying deficiencies in the company’s current good manufacturing practices and/or quality systems; Warning Letters identifying violations of FDA regulations that could result in product holds, recalls, restrictions on future clearances by the FDA and/or civil penalties;

 

   

the failure to obtain, limitations on the use of, or the loss of, patent and other intellectual property rights, and the failure of efforts to protect our intellectual property rights against infringement and legal challenges that can increase our costs;

 

   

difficulties obtaining necessary components or raw materials used in the company’s products and/or price increases from the company’s suppliers of critical components or raw materials or other interruptions of the supply chain; and

 

   

customers that may limit the number of manufacturers or vendors from which they will purchase products, which can result in the company’s inability to sell products to or contract with large hospital systems, integrated delivery networks or group purchasing organizations.

Governmental action, including:

 

   

the impact of continued healthcare cost containment;

 

   

new laws and judicial decisions related to health care availability, payment for healthcare products and services or the marketing and distribution of products, including legislative or administrative reforms to the United States Medicare and Medicaid systems or other United States or international reimbursement systems in a manner that would significantly reduce or eliminate reimbursements for procedures that use the company’s products;

 

   

changes in the FDA and/or foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;

 

   

the impact of more vigorous compliance and enforcement activities affecting the healthcare industry in general or the company in particular;

 

   

changes in the tax or environmental laws or standards affecting our business;

 

26


Table of Contents
   

changes in laws that could require facility upgrades or process changes and could affect production rates and output; and

 

   

compliance costs and potential penalties and remediation obligations in connection with environmental laws, including regulations regarding air emissions, waste water discharges and solid waste.

Legal disputes, including:

 

   

disputes over intellectual property rights;

 

   

product liability claims, including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including with respect to our Composix Kugel product;

 

   

claims asserting securities law violations;

 

   

claims asserting, and/or subpoenas seeking information regarding, violations of law in connection with federal and/or state healthcare programs such as Medicare or Medicaid;

 

   

derivative shareholder actions;

 

   

claims and subpoenas asserting antitrust violations;

 

   

environmental claims, including risks relating to accidental contamination or injury from the use of hazardous materials in the company’s manufacturing, sterilization and research activities and the potential for the company to be held liable for any resulting damages; and

 

   

commercial disputes, including disputes over distribution agreements, license agreements, manufacturing/supply agreements, development/research agreements, acquisition or sale agreements, and insurance policies.

General economic conditions, including:

 

   

international and domestic business conditions;

 

   

political or economic instability in foreign countries;

 

   

interest rates;

 

   

foreign currency exchange rates; and

 

   

changes in the rate of inflation.

 

     Other factors beyond our control, including catastrophes, both natural and man-made, earthquakes, floods, fires, explosions, acts of terrorism or war.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The quantitative and qualitative disclosures about market risk are discussed in Item 7A in the company’s 2007 Annual Report on Form 10-K. There have been no material changes in information reported since the year ended December 31, 2007.

Item 4. Controls and Procedures

The company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the company’s reports under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the company’s management, including its

 

27


Table of Contents

Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Any controls and procedures, no matter how well defined and operated, can provide only reasonable assurance of achieving the desired control objectives.

The company’s management, with the participation of the company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the company’s disclosure controls and procedures as of June 30, 2008. Based upon that evaluation, the company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2008, the design and operation of the company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) provide reasonable assurance that the disclosure controls and procedures are effective to accomplish their objectives.

 

28


Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

In the ordinary course of business, the company is subject to various legal proceedings and claims, including for example, product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company were to be determined to be invalid or unenforceable, the company might be required to reduce the value of the patent on the company’s balance sheet and to record a corresponding charge, which could be significant in amount.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for any remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined.

The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial position or liquidity. However, one or more of the proceedings could be material to the company’s business and results of operations for a future period.

On November 27, 2006, the company’s Urological Division received a subpoena issued by the Department of Health and Human Services, Office of Inspector General, under the authority of the federal healthcare fraud and false claims statutes. The subpoena seeks documents related to the division’s brachytherapy business. The company is cooperating with the government’s request and is in the process of responding to the subpoena. At this stage of the inquiry, the likelihood of an adverse outcome cannot be assessed. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period.

As of July 25, 2008, approximately 735 federal and 1,100 state lawsuits involving individual claims by approximately 1,940 plaintiffs, as well as three putative class actions, have been filed or asserted against the company with respect to its Composix® Kugel® product intended for ventral hernia repair (collectively, the “Composix Claims”). One class action lawsuit consolidates eight previously filed class action lawsuits. The company voluntarily recalled certain sizes and lots of the product beginning in December 2005. The actions generally seek damages for personal injury resulting from use of the product. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. On June 22, 2007, the Judicial Panel on Multidistrict Litigation transferred Composix lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of

 

29


Table of Contents

Rhode Island. Approximately 1,075 of the state lawsuits, involving individual claims by approximately 1,090 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. In March 2008, the Superior Court of the State of Rhode Island directed that certain lawsuits had improperly consolidated numerous plaintiffs and ordered the re-filing of complaints on behalf of those plaintiffs, resulting in an increase in the number of lawsuits but a decrease in the number of plaintiffs in lawsuits pending in that court.

The Composix Claims are at a preliminary stage. In the vast majority of these cases, we have not yet obtained and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, we are unable to fully evaluate the claims or determine the time frame in which they may be resolved. As in most litigation of this nature, the Composix Claims present a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. We believe that many settlements and judgments relating to the Composix Claims may be covered in whole or in part under our product liability insurance policies. While the company intends to vigorously defend the Composix Claims, it cannot give any assurances that the Composix Claims will not have a material adverse impact on the company’s result of operations in future periods or the company’s financial position or liquidity.

On February 21, 2007, Southeast Missouri Hospital filed a putative class action complaint on behalf of itself and all others similarly situated against the company and another manufacturer under the caption Southeast Missouri Hospital, et al. v. C. R. Bard, Inc., et al. (Civil Action No. 1:07-cv-00031, United States District Court, Eastern District of Missouri, Southeastern District). The complaint was later amended to add St. Francis Medical Center as an additional named plaintiff. Co-defendant Tyco International, Inc.’s motion to dismiss was granted and consequently Tyco is no longer a party to the action. The plaintiffs allege that the company conspired to exclude competitors from the market and that the company sought to maintain the company’s market share by engaging in conduct in violation of state and federal antitrust laws. The plaintiff seeks injunctive relief and money damages. Antitrust damages are subject to trebling. The company intends to defend this matter vigorously. At this time, it is not possible to assess the likelihood of an adverse outcome or determine an estimate, or a range of estimates, of potential damages. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period or the company’s financial position or liquidity.

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135. The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the court is currently assessing Gore’s assertion that the patent is unenforceable due to inequitable conduct. Because the company considers this matter a gain contingency, no amounts have been recorded as of June 30, 2008.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

    Issuer Purchases of Equity Securities
        Open Market Purchases

Period

  Employee
Benefit Plan
Shares
Surrendered
For Taxes(1)
  Total Number
of Shares
Purchased(2)
  Average Price
Paid Per Share
  Total Number
of Shares

Purchased as
Part of Publicly
Announced
Programs(2)
  Maximum
Approximate
Dollar Value of
Shares

that May Yet
Be Purchased

Under Plans or
Programs(2)

April 1 - April 30, 2008

  3,480   —     $ —     —     $ 206,652,414

May 1 - May 31, 2008

  3,743   125,000     91.94   125,000     195,159,674

June 1 - June 30, 2008

  137   —       —     —       195,159,674
                       

Total

  7,360   125,000   $ 91.94   125,000   $ 195,159,674
                       

 

30


Table of Contents

 

(1) Transactions represent the purchase of restricted shares from employees to satisfy tax withholding requirements on the vesting of equity-based awards. None of these transactions were made in the open market.
(2) On October 10, 2007, the Board of Directors approved the repurchase of up to $500 million of common stock of the company.

Item 4. Submission of Matters to a Vote of Security Holders

The company’s annual meeting of shareholders was held on April 16, 2008. The information set forth in Part II, Item 4 of the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2008 is incorporated herein by reference.

Item 5. Other Information

Our policy governing transactions in our securities by our directors, executive officers and other specified employees permits such persons to adopt trading plans pursuant to Rule 10b5-1 of the Exchange Act. We anticipate that from time to time, the company’s executive officers may establish trading plans relating to our common stock under Rule 10b5-1. Our current intention is to disclose details regarding individual trading plans on our website.

Item 6. Exhibits

 

(a) Exhibit 10bs* – 2003 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated).
(b) Exhibit 12.1 – Computation of Ratio of Earnings to Fixed Charges
(c) Exhibit 31.1 – Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer
(d) Exhibit 31.2 – Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer
(e) Exhibit 32.1 – Section 1350 Certification of Chief Executive Officer
(f) Exhibit 32.2 – Section 1350 Certification of Chief Financial Officer

 

   * This exhibit constitutes a management contract or a compensatory plan or arrangement.

 

31


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    C. R. BARD, INC.
          (Registrant)
   

/s/    TODD C. SCHERMERHORN        

   

Todd C. Schermerhorn

Senior Vice President and

Chief Financial Officer

Date: July 28, 2008

   
   

/s/    FRANK LUPISELLA JR.        

   

Frank Lupisella Jr.

Vice President and Controller

 

32